Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does MEPOLIZUMAB Cause Venous pressure jugular increased? 30 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 30 reports of Venous pressure jugular increased have been filed in association with MEPOLIZUMAB (Nucala). This represents 0.1% of all adverse event reports for MEPOLIZUMAB.

30
Reports of Venous pressure jugular increased with MEPOLIZUMAB
0.1%
of all MEPOLIZUMAB reports
0
Deaths
30
Hospitalizations

How Dangerous Is Venous pressure jugular increased From MEPOLIZUMAB?

Of the 30 reports, 30 (100.0%) required hospitalization.

Is Venous pressure jugular increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for MEPOLIZUMAB. However, 30 reports have been filed with the FAERS database.

What Other Side Effects Does MEPOLIZUMAB Cause?

Asthma (11,033) Dyspnoea (9,192) Wheezing (6,093) Product dose omission issue (5,873) Cough (4,577) Pneumonia (4,107) Therapeutic product effect incomplete (4,106) Drug ineffective (3,880) Loss of personal independence in daily activities (3,566) Fatigue (2,656)

What Other Drugs Cause Venous pressure jugular increased?

BISOPROLOL (41) FUROSEMIDE (35) PREDNISONE (34) ALBUTEROL (30) BUDESONIDE (30) BUDESONIDE\FORMOTEROL (30) CICLESONIDE (30) DIGOXIN (30) FLUTICASONE FUROATE\VILANTEROL TRIFENATATE (30) IPRATROPIUM (30)

Which MEPOLIZUMAB Alternatives Have Lower Venous pressure jugular increased Risk?

MEPOLIZUMAB vs MEPROBAMATE MEPOLIZUMAB vs MERCAPTOPURINE MEPOLIZUMAB vs MEROPENEM MEPOLIZUMAB vs MEROPENEM ANHYDROUS MEPOLIZUMAB vs MESALAMINE

Related Pages

MEPOLIZUMAB Full Profile All Venous pressure jugular increased Reports All Drugs Causing Venous pressure jugular increased MEPOLIZUMAB Demographics